His primary scientific interests are in Ovarian cancer, Internal medicine, Surgery, Oncology and Cancer. His research integrates issues of Cancer research, Carcinoma, Ascites and Gynecology in his study of Ovarian cancer. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Endocrinology.
His research investigates the connection with Surgery and areas like Hazard ratio which intersect with concerns in Retrospective cohort study. Jalid Sehouli works mostly in the field of Oncology, limiting it down to concerns involving Clinical trial and, occasionally, Randomized controlled trial. His Cancer study integrates concerns from other disciplines, such as Prospective cohort study, Disease and Palliative care.
His main research concerns Internal medicine, Ovarian cancer, Oncology, Surgery and Chemotherapy. His Carboplatin, Ascites and Recurrent Ovarian Cancer study in the realm of Internal medicine interacts with subjects such as In patient. His work in Carboplatin is not limited to one particular discipline; it also encompasses Paclitaxel.
He usually deals with Ovarian cancer and limits it to topics linked to Cancer research and Ovarian carcinoma. His Oncology research is multidisciplinary, incorporating perspectives in Clinical trial, Phases of clinical research, Topotecan, Advanced ovarian cancer and Bevacizumab. Surgery is often connected to Cervical cancer in his work.
His primary areas of study are Internal medicine, Ovarian cancer, Oncology, Cancer research and Chemotherapy. His study on Quality of life, Cancer and Bevacizumab is often connected to In patient as part of broader study in Internal medicine. The various areas that Jalid Sehouli examines in his Ovarian cancer study include Serous fluid, Ascites, Clinical endpoint, Disease and Stage.
His research in Serous fluid intersects with topics in Ovarian carcinoma, Biomarker and Tissue microarray. His work carried out in the field of Oncology brings together such families of science as Debulking, Serous ovarian cancer, Vulvar cancer, Recurrent Ovarian Cancer and Cohort.
Jalid Sehouli mainly investigates Internal medicine, Ovarian cancer, Oncology, Cancer research and Serous fluid. His research in the fields of Chemotherapy and Carboplatin overlaps with other disciplines such as In patient. His Ovarian cancer study deals with the bigger picture of Cancer.
His work in Oncology covers topics such as Recurrent Ovarian Cancer which are related to areas like Clinical trial and Surgery. In his research, Immunohistochemistry and Meta-analysis is intimately related to Biomarker, which falls under the overarching field of Cancer research. His studies deal with areas such as Ovarian carcinoma, Machine learning, Tissue microarray and Artificial intelligence as well as Serous fluid.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann.
The New England Journal of Medicine (2011)
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine;Uwe Wagner;Elisabeth Aavall-Lundqvist;Val Gebski.
Journal of Clinical Oncology (2010)
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Philipp Harter;Andreas du Bois;Maik Hahmann;Annette Hasenburg.
Annals of Surgical Oncology (2006)
Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors.
Carsten Denkert;Jan Budczies;Tobias Kind;Wilko Weichert.
Cancer Research (2006)
Systematic review and meta-analysis of antibiotic therapy for bone and joint infections
Dirk Stengel;Kai Bauwens;Jalid Sehouli;Axel Ekkernkamp.
Lancet Infectious Diseases (2001)
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM.
Steffen Runz;Sascha Keller;Christian Rupp;Alexander Stoeck;Alexander Stoeck.
Gynecologic Oncology (2007)
Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes
Sascha Keller;Anne-Kathleen König;Frederik Marmé;Steffen Runz.
Cancer Letters (2009)
Magnetic nanoparticles for interstitial thermotherapy--feasibility, tolerance and achieved temperatures.
Peter Wust;Uwe Gneveckow;Manfred Johannsen;Dirk Böhmer.
International Journal of Hyperthermia (2006)
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential
Ivo Meinhold-Heerlein;Dirk Bauerschlag;Dirk Bauerschlag;Felix Hilpert;Petre Dimitrov.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N. Colombo;C. Sessa;A. du Bois;J. Ledermann.
Annals of Oncology (2019)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: